Pearl

Computer vision pathology detection on radiographs is the product. The company was founded specifically to build it, and the detection model is what a practice buys.

The panoramic clearance was supported by a standalone performance study and a fully crossed multi reader, multi case study, with the vendor reporting stable performance across gender, geography, and imaging device subgroups. MRMC is the appropriate study design for reader assistance claims and its use here is the substantive point. A published study is cited in which operator diagnostic accuracy rose from 82 percent to 98 percent with the tool. Graded on evidence design and regulatory validation; this index does not re verify the underlying results, and the 95 percent accuracy and 37 percent more disease figures remain vendor stated.

Among the most disciplined regulatory records in the index, and stated per product and per modality rather than as a blanket claim. Clearances span 2D intraoral (bitewing, periapical), extraoral panoramic, 3D CBCT via Second Opinion 3D, a pediatric indication down to age four, and AI segmentation. The company describes itself as the first dental AI company cleared for both 2D and 3D radiologic analysis and reports regulatory clearance in 120 countries.

Subgroup performance was evaluated and reported across gender, geography, and imaging device type as part of the panoramic clearance, which is a genuine fairness disclosure and rare in this index. Held back from A because no standing governance framework, model update policy, or third party AI audit was retrieved beyond the clearance documentation.

No public pricing. Contact the vendor. Sold to dental practices and multi office networks through demo and sales engagement; no published rate card.

Tightly and clearly bounded: dental practices, across bitewing, periapical, panoramic, and CBCT imaging, with an explicit pediatric indication from age four. Narrow scope precisely stated is what this axis rewards.